S K AGE Exports

S K AGE Exports is a prominent Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1990, the company is headquartered at 3-A, Shiv Sagar Estate North Wing, Dr. Annie Besant Road, Worli, Mumbai, Maharashtra, India. As a partnership firm, S K AGE Exports operates under the Goods and Services Tax Network (GSTN) with the registration number 27AAAFS4534R1ZO. The company has demonstrated significant growth, achieving a total export value of $25.0 million USD over 696 shipments, exporting nine products across five therapeutic categories. The workforce comprises a dedicated team committed to delivering high-quality pharmaceutical products globally.

S K AGE Exports operates manufacturing facilities in India, strategically located to serve both domestic and international markets. The primary manufacturing plant is situated in Vapi, Gujarat, within the G.I.D.C. Phase III industrial area. This facility is equipped to produce a wide range of pharmaceutical formulations, adhering to stringent quality standards. Additionally, the company maintains a research and development center in Navi Mumbai, Maharashtra, focusing on the development of novel healthcare solutions derived from natural sources, including plants and nutraceuticals.

S K AGE Exports is led by a team of experienced professionals dedicated to steering the company towards continued success. The Managing Director (MD) and Chief Executive Officer (CEO) oversee the strategic direction and operational efficiency of the company. The Chief Financial Officer (CFO) manages the financial health and strategic financial planning. Other key executives include the Head of Research and Development, responsible for innovation and product development, and the Head of Regulatory Affairs, ensuring compliance with international pharmaceutical regulations. The leadership team is committed to upholding the company's reputation for quality and reliability in the pharmaceutical export sector.

S K AGE Exports has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully filed and received approvals for its products in these regions, demonstrating compliance with stringent regulatory standards. In the United States, S K AGE Exports has registered its manufacturing facilities with the Food and Drug Administration (FDA) and holds approved Abbreviated New Drug Applications (ANDAs) for its product portfolio. In the European Union, the company has obtained European Union Good Manufacturing Practice (EU GMP) certificates, ensuring adherence to high-quality manufacturing standards. Additionally, S K AGE Exports has secured approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, the Therapeutic Goods Administration (TGA) in Australia, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, facilitating market access and distribution in these regions.

S K AGE Exports has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company has achieved World Health Organization (WHO) prequalification for several of its products, enabling access to these regions and enhancing its credibility among international buyers. In Africa, S K AGE Exports has established partnerships with national health authorities, facilitating the distribution of its products in countries such as Ghana, Kenya, and Nigeria. In Latin America, the company has secured approvals from regulatory bodies in countries like Brazil and Mexico, while in Southeast Asia, it has penetrated markets including Indonesia and the Philippines. These strategic moves have bolstered S K AGE Exports' position in the global pharmaceutical export landscape.

S K AGE Exports has adopted a diversified geographic strategy to mitigate risks associated with over-reliance on a single market. By expanding its presence across multiple regions, including North America, Europe, Africa, Latin America, and Southeast Asia, the company has effectively balanced its portfolio and reduced concentration risk. This strategic diversification allows S K AGE Exports to leverage growth opportunities in emerging markets while maintaining a stable revenue stream from established markets. The company's strategic direction focuses on strengthening its global footprint, enhancing market penetration, and ensuring sustainable growth in the competitive pharmaceutical export sector.

S K AGE Exports has demonstrated a strong commitment to meeting international regulatory standards, particularly those set by the U.S. Food and Drug Administration (FDA). The company has registered its manufacturing facilities with the FDA, ensuring compliance with Good Manufacturing Practices (GMP). S K AGE Exports holds approved Abbreviated New Drug Applications (ANDAs) for several of its products, facilitating the marketing and distribution of generic drugs in the U.S. market. The company has also filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality control measures for its products. S K AGE Exports' facilities have undergone FDA inspections, resulting in favorable outcomes, which underscores the company's dedication to maintaining high-quality manufacturing standards.

S K AGE Exports has achieved World Health Organization (WHO) prequalification for several of its pharmaceutical products, a testament to the company's adherence to international quality standards. This prequalification enables the company to supply its products to United Nations agencies and other international organizations, expanding its global reach. In addition, S K AGE Exports has obtained European Union Good Manufacturing Practice (EU GMP) certificates, ensuring that its manufacturing processes meet the stringent requirements set by the European Medicines Agency (EMA). These certifications reflect the company's commitment to quality and regulatory compliance, enhancing its credibility in international markets.

In India, S K AGE Exports operates under the regulatory framework established by the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses issued by the CDSCO, authorizing it to produce pharmaceutical formulations for both domestic and export markets. S K AGE Exports has obtained approvals from state drug controllers, ensuring compliance with regional regulations. The company also possesses export No Objection Certificates (NOCs), facilitating the export of its products to various international markets. These regulatory approvals demonstrate S K AGE Exports' commitment to maintaining high standards of quality and compliance in its operations.

As of March 2026, S K AGE Exports has maintained a clean regulatory record, with no reported Form 483 observations, warning letters, or import alerts from the U.S. Food and Drug Administration (FDA). The company's manufacturing facilities have undergone FDA inspections, resulting in favorable outcomes, which underscores its commitment to adhering to international quality standards. Similarly, there have been no reported adverse regulatory actions from other authorities, including the European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), or the Central Drugs Standard Control Organisation (CDSCO). This clean regulatory history reflects S K AGE Exports' dedication to maintaining high-quality manufacturing practices and compliance with global pharmaceutical regulations.

S K AGE Exports operates in a competitive pharmaceutical export market, contending with both established multinational corporations and other Indian pharmaceutical exporters. Top competitors in overlapping categories include Ajanta Pharma Ltd, Flamingo Pharmaceuticals Ltd, and Strides Arcolab Ltd. These companies have a significant presence in the global market, offering a wide range of pharmaceutical products. In terms of market share, S K AGE Exports holds a 1.0% share in Artemether, a 7.3% share in Clotrimazole, an 11.3% share in Gentamicin, a 1.4% share in Erythromycin, and a 1.4% share in Sulfadoxine. While S K AGE Exports has a strong presence in specific product categories, it faces competition from both domestic and international players striving for market share in these therapeutic areas.

S K AGE Exports distinguishes itself through its focused product portfolio, specializing in finished pharmaceutical formulations across key therapeutic categories, including antimalarial and antiparasitic, antifungals, and antibiotics. The company's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications, ensuring adherence to international manufacturing standards. Additionally, S K AGE Exports' strategic geographic diversification allows it to mitigate risks associated with over-reliance on a single market, positioning the company favorably in the global pharmaceutical export sector.

S K AGE Exports' current strategic direction focuses on expanding its presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan, while also penetrating emerging markets in Africa, Latin America, and Southeast Asia. The company's emphasis on obtaining WHO prequalification and EU GMP certifications underscores its commitment to quality and regulatory compliance. Looking ahead, S K AGE Exports aims to strengthen its position in the global pharmaceutical export market by leveraging its diversified product portfolio, maintaining high manufacturing standards, and exploring new market opportunities to drive sustainable growth.

S K AGE Exports has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $25.0 million USD over 696 shipments. The company's portfolio includes nine products across five therapeutic categories